Enterocolitis associated with glofitamab—First report and clinicopathological findings in three cases
Sign Up to like & getrecommendations! Published in 2025 at "British Journal of Haematology"
DOI: 10.1111/bjh.20052
Abstract: Glofitamab is a CD3‐CD20 bispecific antibody used to treat B‐cell non‐Hodgkin lymphoma. We describe three cases of enterocolitis occurring with glofitamab at a single institution. Similarities between cases include onset post cycle 4–5, moderately elevated… read more here.
Keywords: cases enterocolitis; three cases; glofitamab first; associated glofitamab ... See more keywords
Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-194333
Abstract: Background: Glofitamab is a CD20xCD3 bispecific antibody that engages and redirects T cells to eliminate B cells. In this Phase II study (NCT03075696) of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), fixed-duration glofitamab monotherapy… read more here.
Keywords: treatment; duration glofitamab; fixed duration; cell ... See more keywords
ARV-393, a PROTAC BCL6 degrader, combined with the CD20×CD3 bispecific glofitamab in a preclinical model of high-grade B-cell lymphoma (HGBCL)
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1520
Abstract: Background: Despite significant progress made in the treatment of non-Hodgkin lymphoma (NHL) through advancements with immunochemotherapy, autologous stem cell transplantation, chimeric antigen receptor T-cell therapies, bispecific antibodies, and other targeted therapies, many patients ultimately experience… read more here.
Keywords: arv 393; combination; cell; bcl6 ... See more keywords
Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2382
Abstract: Background Glofitamab (a CD20×CD3 bispecific antibody) has been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). In clinical practice, we observed that some patients received glofitamab before leukapheresis. Theoretically, glofitamab exerts… read more here.
Keywords: car therapy; group; exposed group; efficacy ... See more keywords
Safety and efficacy of glofitamab in combination with lenalidomide in relapsed or refractory central nervous system lymphoma: Real-world data
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7260
Abstract: Background: Central nervous system lymphoma (CNSL) is a rare and aggressive subtype of non-Hodgkin lymphoma, predominantly diffuse large B-cell lymphoma (DLBCL)， characterized by insidious onset, rapid progression, and high recurrence rate. Conventional therapies, including craniotomy,… read more here.
Keywords: central nervous; treatment; nervous system; combination ... See more keywords
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2021 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021005954
Abstract: Key Points Glofitamab induced dose-dependent induction of cytokines and T-cell margination, proliferation, and activation in peripheral blood. Tumor cell intrinsic factors (eg, TP53 and MYC signaling) are associated with resistance to glofitamab. read more here.
Keywords: pharmacodynamics molecular; molecular correlates; correlates response; glofitamab ... See more keywords
Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.7519
Abstract: 7519 Background: Glofitamab (RG6026), a T-cell-engaging, bispecific, full-length antibody, allows bivalent binding to CD20 (B-cells), and monovalent binding to CD3 (T-cells). In NP30179 (NCT03075696), an ongoing multicenter, Phase I dose-escalation and expansion study, 0.6–25mg glofitamab… read more here.
Keywords: response; response rates; efficacy; updated efficacy ... See more keywords